Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BLU 222 (Primary) ; Carboplatin (Primary) ; Fulvestrant (Primary) ; Ribociclib (Primary)
  • Indications Advanced breast cancer; Endometrial cancer; Gastric cancer; HER2 negative breast cancer; Ovarian cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms VELA
  • Sponsors Blueprint Medicines

Most Recent Events

  • 17 Jan 2025 Status changed from recruiting to active, no longer recruiting.
  • 30 Oct 2024 According to a Blueprint Medicines media release, company plans to complete Phase 1 combination dose escalation for BLU-222 by end of year to inform registration plans.
  • 04 Jun 2024 Results assessing safety and efficacy were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top